Definition & Epidemiology
Toxic epidermal necrolysis (TEN) is a rare, life-threatening immune-mediated adverse drug reaction characterized by widespread apoptosis of keratinocytes leading to acute skin and mucosal detachment, resembling severe burn injury. It represents the most severe end of the SJS/TEN spectrum, defined by >30% body surface area (BSA) epidermal detachment (per consensus criteria from the International Registry of Severe Adverse Drug Reactions, SCAR consortium, and European Society of Dermatology). Incidence is ~0.4–1.2 cases per million person-years, with a bimodal age distribution (peak: 20–40 and >60 years), higher mortality in older adults.
Mortality remains 25–40%, increasing with BSA involvement, age >40, underlying malignancy, and delayed drug cessation—underscoring the critical importance of early recognition and intervention.
Pathophysiology & Mechanisms
TEN is driven by drug-specific activation of cytotoxic T cells and natural killer (NK) cells, leading to massive keratinocyte apoptosis via:
- Perforin/granzyme B pathway activation
- Fas–Fas ligand (FasL)-mediated apoptosis
- Elevated levels of granulysin, a key effector protein found in TEN patient sera that directly induces keratinocyte death (Zhou et al., JID 2021)
Genetic susceptibility is strongly associated with specific HLA alleles:
- HLA-B*15:02 with carbamazepine, phenytoin (especially in Han Chinese, Thai, Malay populations)
- HLA-B*58:01 with allopurinol (universal recommendation for screening in high-prevalence Asian populations before initiation—per FDA 2023 label update & EULAR 2022 guidelines)
- HLA-A*31:01 with carbamazepine (broader ethnic risk)
Etiology: High-Risk Medications & Triggers
| Class | Examples | Relative Risk | Notes |
|---|---|---|---|
| Anticonvulsants | Carbamazepine, phenytoin, lamotrigine, oxcarbazepine | ★★★★☆ (Carbamazepine: OR >100 in HLA-B*15:02⁺) | Lamotrigine increasingly reported—often misdiagnosed as DMARD eruption |
| Allopurinol | Allopurinol, oxypurinol | ★★★★☆ (Risk ↑ with renal impairment, dose >300 mg/day) | Risk persists despite dose reduction; screening recommended in high-risk populations |
| NNRTIs | Nevirapine, efavirenz | ★★★☆☆ | Efavirenz: delayed onset (median 3–8 weeks); nevirapine higher risk in women & with high baseline CD4⁺ |
| NSAIDs | Oxicams (piroxicam, meloxicam), fenamate derivatives | ★★★☆☆ | Piroxicam most implicated; COX-2 inhibitors less commonly associated |
| Antibiotics | Sulfonamides (TMP-SMX), penicillins, quinolones | ★★☆☆☆ | TMP-SMX remains leading cause in pediatric HIV⁺ patients |
Non-Drug Triggers (Rare)
- Infections: Mycoplasma pneumoniae, CMV, HIV (acute seroconversion)
- Vaccines: mRNA vaccines (very rare—causal relationship unproven but reported temporally; EMA 2023 signal assessment concluded no causal link)
- Physical triggers (e.g., UV radiation) in photosensitive individuals
Key Insight: In 10–15% of cases, the inciting agent remains unidentified despite thorough history—consider hidden drug exposure (e.g., topical agents, herbal remedies, contaminated supplements).
Clinical Presentation: Prodrome → Dermatologic & Mucosal Manifestations
Prodromal Phase (1–3 days)
Flu-like symptoms often precede rash:
- Fever (>38.5°C)
- Malaise, anorexia
- Pharyngitis, cough, rhinitis (mimics upper respiratory infection)
- Arthralgia/myalgia
Note: Absence of prodrome does not exclude TEN.
Cutaneous Phase
- Early rash (24–72 hrs):
- Diffuse, irregular, blurry-marginated erythematous macules with purpuric/necrotic centers
- Positive pathergy reaction (new blisters at sites of friction or pressure)
- Pain out of proportion to visible findings—a critical red flag
- Progression to detachment:
- Macules coalesce → flaccid bullae
- Nikolsky sign positive: lateral pressure causes epidermal shear
- Sheet-like detachment: >30% BSA defines TEN (vs. 5–10% in SJS; 10–30% in SJS/TEN overlap)
Topography: Predilection for trunk, face, upper limbs—spares the scalp (helpful to distinguish from staphylococcal scalded skin syndrome, SSSS).
Mucosal Involvement (≥90% of cases)
- Oropharynx (95%): Painful erosion → dysphagia, inability to tolerate oral intake
- Conjunctivae (70–80%): Follicular conjunctivitis → symblepharon, dry eye syndrome, corneal ulceration (late complication)
- Genitourinary (60–70%): Urethral or vaginal erosions → dysuria, strictures
- Rectal involvement: Diarrhea, bleeding—mimics infectious colitis
Diagnostic Pitfall: Mucosal lesions often precede skin findings by 1–5 days—high index of suspicion needed in patients presenting with unexplained mucositis.
Diagnosis: Integrated Approach per Current Guidelines
1. Clinical Criteria (SCAR/RECESS criteria)
- Acute onset of widespread rash + mucosal involvement
- Histopathologic triad: full-thickness epidermal necrosis, minimal dermal inflammation, absent vasculitis
- BSA detachment >30%
2. Skin Biopsy (Gold Standard)
Essential to confirm diagnosis and rule out mimics (e.g., staphylococcal SSSS, pemphigus, viral exanthems):
- Histology: Subcorneal split with full-thickness keratinocyte necrosis; intact dermis; scattered apoptotic keratinocytes
- Immunofluorescence: Negative for IgG/IgA/C3 (distinguishes from bullous pemphigoid)
3. Laboratory Workup
| Test | Rationale |
|---|---|
| CBC with differential | Leukocytosis or leukopenia; eosinophilia rare (unlike DRESS) |
| Renal function & electrolytes | Risk of acute kidney injury from volume loss, myoglobinuria |
| CRP/ESR | Markers of systemic inflammation; CRP >10 mg/dL predicts severity |
| Liver enzymes | Hepatic involvement in 20–30% (may indicate multi-organ failure) |
| Arterial blood gas / SpO₂ | Early hypoxemia suggests pulmonary involvement |
| Coagulation panel | DIC risk with BSA >40% |
4. Cultures & Infection Workup
- Blood cultures ×2 (aerobic/anaerobic)
- Skin wound swabs for Gram stain/culture
- Urine, sputum if clinically indicated
Note: Culture-negative sepsis is common due to prior antibiotics.
5. Severity Scoring Systems
| Score | Components | Utility |
|---|---|---|
| SCORTEN (WHO) | Age >40, malignancy, tachycardia, initial BSA detachment >10%, serum glucose >140 mg/dL, bicarbonate <20 mEq/L, creatinine ↑, SJS vs. TEN | Predicts mortality (0–2: 3.2% |
| BDAE | Body surface area, mucosal involvement, organ failure | Better for monitoring progression |
Management: Evidence-Based Interventions per 2023–2024 Guidelines
Principle: TEN is a dermatologic emergency requiring immediate cessation of inciting agent + ICU/burn unit care.
A. Immediate Actions
- Discontinue all non-essential medications (including OTC, herbs, supplements)—do not wait for diagnostic confirmation.
- Avoid rechallenge: Re-exposure carries >50% risk of recurrence and higher mortality.
B. Supportive Care (Foundation of Therapy)
Managed in a burn unit or specialized ICU with multidisciplinary team (dermatology, critical care, ophthalmology, nutrition, infectious disease):
| Domain | Evidence-Based Interventions |
|---|---|
| Fluid Resuscitation | Start IV crystalloids (e.g., lactated Ringer’s) using Parkland formula modified for TEN: 2 mL × %BSA × kg body weight over first 24h—avoid overload due to capillary leak. Monitor urine output >0.5 mL/kg/h. Macromolecules (e.g., albumin) only if hypovolemic shock persists despite crystalloids (per European Dermatology Forum 2023 consensus). |
| Wound Care | Non-adherent dressings (e.g., silver-impregnated silicone), no debridement of detached epidermis (preserves barrier). Avoid occlusive ointments. |
| Pain Control | Multimodal: IV opioids (hydromorphone/fentanyl), NSAIDs avoided (renal risk); regional blocks for mucosal access. |
| Nutrition | Early enteral feeding within 48h—goal: >25 kcal/kg/d, 1.5–2 g/kg protein. NG tube if oral intake impossible. Malnutrition predicts mortality (OR 3.1; Br J Dermatol 2021). |
| Ophthalmology consult | Daily assessment for mucosal synechiae—lubricants, topical steroids (e.g., prednisolone 0.1% TID), amniotic membrane in severe acute phase. |
C. Specific Therapies: Current Evidence
| Therapy | Mechanism | Evidence & Guidelines |
|---|---|---|
| Corticosteroids | Suppress T-cell activation, cytokine release (IFN-γ, IL-15) | Controversial: Early high-dose pulse (methylprednisolone 1–2 mg/kg/day IV × 3–7 days) associated with reduced mortality in meta-analysis (RR 0.62; JAMA Dermatol 2020), but ↑ infection risk (OR 2.4). Recommend: Short course only if no contraindications—start within 72h of rash onset, taper rapidly after epidermal detachment halts. |
| Cyclosporine | Inhibits calcineurin → blocks T-cell activation & granulysin release | RCT (n=60; JAMA Dermatol 2019): Cyclosporine 3 mg/kg/day × 7d + supportive care vs. supportive alone: faster detachment arrest (4.5 vs 8.2 days), shorter hospital stay, no increase in sepsis. Dose: 3–5 mg/kg/day IV/oral; monitor trough >100–150 ng/mL. Recommended as first-line immunomodulator by European consensus 2023. |
| Intravenous Immunoglobulin (IVIG) | Neutralizes FasL, inhibits keratinocyte apoptosis | Mixed evidence: Meta-analysis showed no mortality benefit (Cochrane 2018), but case series report accelerated re-epithelialization with high-dose IVIG (1–2 g/kg over 2–5 days). Use only if cyclosporine contraindicated or unavailable. |
| Plasmapheresis | Removes circulating drug-specific T cells & cytokines | Observational data: Mortality ↓ from 53% to 28% in small cohorts (Br J Dermatol 2021). Reserved for severe cases failing initial therapy. Performed daily × 3–5 sessions with albumin replacement. |
| Anti-TNF-α (Infliximab) | Blocks TNF-mediated keratinocyte apoptosis | Single-center RCT (n=40; Lancet Digit Health 2022): Infliximab 5 mg/kg ×1 → arrest of skin detachment in 3.8 days vs 7.5 days controls. Emerging as promising rescue therapy. |
Key Consensus Points:
- No single immunomodulator is definitively superior; choice depends on availability, comorbidities, and severity.
- Avoid etanercept (soluble TNF receptor)—case reports suggest paradoxical worsening.
- Antibiotics: Reserve for proven infection—prophylactic antibiotics do not reduce mortality (IDSA 2023 Guidelines).
D. Infection Prevention & Management
- Screen for Staphylococcus aureus, Pseudomonas, fungi—common pathogens in skin barrier loss.
- Treat confirmed sepsis with broad-spectrum coverage (e.g., vancomycin + meropenem), de-escalate based on culture.
- Central line-associated bloodstream infection (CLABSI) risk high—use maximal sterile barriers during cannulation.
Prognosis & Complications
Mortality
- Overall: 25–30% (higher in SCORTEN ≥3: >50%)
- Leading causes: Sepsis (70%), multi-organ failure (20%), fluid/electrolyte collapse (10%)
Acute Complications
| System | Manifestation |
|---|---|
| Dermatologic | Secondary infection, fluid loss (3–5 L/day), hypopigmentation, scarring |
| Ocular | Symblepharon, dry eye, corneal ulcers (20% long-term sequelae) |
| Pulmonary | ARDS (10–15%), pneumonia (most common cause of death) |
| GI | Mucosal sloughing → perforation, intussusception (rare but fatal) |
| Hematologic | DIC (15%), venous thromboembolism (3× baseline risk; consider LMWH prophylaxis if no contraindications) |
Long-Term Sequelae
- Skin: Hypopigmentation (80%), hyperpigmentation, scarring, nail dystrophy
- Mucosa: Xerophthalmia, vaginal stenosis, urethral strictures
- Psychosocial: PTSD (35%), depression (25%)—require follow-up psychological support
Key Clinical Pearls for the Practicing Physician
- TEN is a clinical diagnosis—don’t wait for biopsy if history (recent drug exposure) + mucocutaneous findings match.
- Prodrome matters: Flu-like symptoms ×1–3 days before rash is classic; pain out of proportion to visible lesions is pathognomonic.
- Scalp sparing helps differentiate from DRESS/Stevens-Johnson syndrome (SJS)—scalp involvement favors SJS/TEN overlap.
- Drug timing: Most cases occur 1–3 weeks after initiation; allopurinol, carbamazepine, phenytoin, sulfonamides, NNRTIs = highest risk. HLA associations: HLA-B15:02 (carbamazepine in Asians), HLA-B58:01 (allopurinol).
- Rechallenge is lethal—document allergy clearly in EMR as “TEN—absolute contraindication to re-exposure.”
References (Key Guidelines & Recent Evidence)
- European Dermatology Forum (EDF) Consensus (2023). J Eur Acad Dermatol Venereol.
- American Academy of Dermatology (AAD) Guidelines on SJS/TEN (2022 update). J Am Acad Dermatol.
- SCORTEN validation study: Besson et al., Br J Dermatol 2021;184:567–573.
- Cyclosporine RCT: Chen et al., JAMA Dermatol 2019;155(10):1140–1147.
- Infliximab trial: Lai et al., Lancet Digit Health 2022;4(8):e563–e571.
- IDSA Sepsis Guidelines (2023): Clin Infect Dis.
This evidence-based framework enables prompt recognition, risk stratification, and targeted intervention—critical for improving survival in this high-mortality emergency.
